Phase 2 Study of Anlotinib Hydrochloric Capsule in Advanced Medullary Thyroid Carcinoma
Inclusion Criteria:
- 1.late medullary thyroid carcinoma; 2.18-70years, ECOG:0-2,Expected survival period
>3 months; 3.Calcitonic≥500pg/ml, thyroid function normal; 4.HB≥100g/L,ANC(Absolute
Neutrophil Count) ≥1.5×109/L;PLT
- 80×109/L ,BIL/Cr in normal range,ALT/AST(aspartate aminotransferase
)≤1.5*ULN(for hepatic metastases,ALT/AST(aspartate aminotransferase )≤5*ULN)
;TG≤ 3.0mmol/L,cholesterol≤7.75mmol/L; LVEF
- LLN. 5.Username contraceptive during the study and after 6 months; 6.Volunteer.
Exclusion Criteria:
- 1.Received vascular endothelial growth inhibitor type of targeted therapy; 2.Subject
was diagnosed with The second cancer; 3.Participated in other clinical trials in four
weeks; 4.Received in other radiotherapy or chemotherapy treatment in four weeks;
5.With AE> 1; 6.Has influence of oral drugs; 7.Brain metastases, spinal cord
compression, cancerous meningitis, or the brain/soft meningeal disease patient; 8.Any
serious or failed to control the disease 9.Artery/venous thrombotic; 10.Coagulant
function abnormality; 11.Arteriovenous thrombosis event; 12.History of psychiatric
drugs abuse or a mental disorder; 13.Immunodeficiency history; 14.Concomitant
diseases.